According to Zacks, “InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC. “
Separately, Roth Capital lowered shares of InMed Pharmaceuticals from a buy rating to a neutral rating in a research note on Monday.
InMed Pharmaceuticals (NASDAQ:INM – Get Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). Analysts expect that InMed Pharmaceuticals will post -0.99 EPS for the current year.
Large investors have recently modified their holdings of the stock. Morgan Stanley increased its stake in InMed Pharmaceuticals by 76.6% during the first quarter. Morgan Stanley now owns 12,581 shares of the company’s stock valued at $41,000 after purchasing an additional 5,459 shares during the last quarter. Renaissance Technologies LLC bought a new stake in InMed Pharmaceuticals during the fourth quarter valued at $58,000. Finally, Empery Asset Management LP bought a new stake in InMed Pharmaceuticals during the first quarter valued at $58,000. Institutional investors and hedge funds own 2.88% of the company’s stock.
InMed Pharmaceuticals Company Profile (Get Rating)
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
- Get a free copy of the StockNews.com research report on InMed Pharmaceuticals (INM)
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.